long intergenic non-protein coding RNA 1150Genealiases: 2G7 · TCONS_00019134
Q-omics provides the consensus-scored LINC01150 profile across patient tissues and cancer cell-line models. LINC01150 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, LINC01150 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, LINC01150 RNA expression shows 14,381 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight STAD, KIRC, and THYM as cancer lineages where LINC01150 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01150 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01150 survival associations across molecular data types. LINC01150 RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01150 RNA expression–survival associations across cancer types. High LINC01150 expression shows unfavorable associations in STAD, LGG and OV, but favorable associations in HNSC, SKCM and LUAD. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify STAD as the clearest survival context for LINC01150 RNA expression.
This table summarizes LINC01150 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01150. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01150 shows lower tumor expression in LUAD, LUSC and COAD and higher tumor expression in KIRC, KIRP and THCA. The KIRC box plot shows higher LINC01150 RNA expression in tumor versus normal tissue (log2 FC = +1.438, t-test p < 0.001).
This table shows molecular features associated with LINC01150 in patient tissues and cancer cell lines. In patient samples, LINC01150 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
